The mechanisms underlying this risk reduction are not exactly clear. However, what we do know is that pravastatin works to reduce stroke. In addition, Pravachol is the first and only drug of its kind to receive FDA clearance for use in reducing the risk of a recurrent heart attack and death from heart disease in patients with normal cholesterol levels. It is important to note that the relationship between cholesterol and the risk of stroke is weak and the evidence suggests that Pravachol reduces the risk of stroke through mechanisms beyond its effect on cholesterol. More than four million people world-wide are believed to suffer a stroke each year.
Stroke is the third-leading cause of death and the leading cause of disability.
Approximately two-thirds of the people who suffer a stroke will experience severe disabilities including paralysis, loss of speech and lapses of memory. In the CARE study patients who received Pravachol reduced their risk of a stroke or TIA by 26 percent, and reduced their risk of recurrent heart attack and death from heart disease by 24 percent. Pravachol therapy is well tolerated by most patients. The most common side effects include mild skin irritation and transient rash and gastrointestinal upset. Pravachol should not be used by people with active liver disease or liver problems, in women who are pregnant or nursing or people who are allergic to any component of the medication.